Zealand Pharma rescue pen books USD 0.6m revenue in Q1

On Thursday, Zealand Pharma has publicized its first quarterly report for 2022, stating that rescue pen Zegalogue has generated sales for DKK 4m (USD 0.6m) during the year’s first three months.

Photo: Zealand Pharma / PR

Zealand Pharma, a biotech firm publicly listed in Denmark, has released its first quarterly report for 2022 on Thursday.

In the first three months of the year, Zealand Pharma’s rescue pen Zegalogue has generated sales of USD 0.6m, while the firm’s insulin pump product, V-Go, booked a revenue of USD 5.3m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs